GBA Presents: THE BARE ESSENTIALS

Beam Global reports Q4 EPS (22c), consensus (21c) 16:16 BEEM Reports Q4 revenue $3.49M, consensus $2.98M. "2021 was a year in which we broke record after record," said Desmond Wheatley, CEO of Beam. "Most importantly, we had material improvements in sales, revenues, deliveries and performance. At the same time, we reduced our costs as a percentage of revenues during the most severe inflationary period in over forty years. We are now seeing dramatic increases in spending on EVs and EV charging infrastructure in the US and internationally so I anticipate that all the positive trends we put in place in 2021 will continue and accelerate in 2022. Acquiring AllCell Technologies uniquely positions us in the industry as the only provider with a proprietary energy storage solution and at the same time it will dramatically reduce our costs. I believe we are very well positioned for 2022."
 
3/8 Ted-

Voyager Therapeutics reports Q4 EPS 15c, consensus (32c) 03/08 VYGR Reports Q4 revenue $28.1M, consensus $14.55M. Cash, cash equivalents and marketable securities as of December 31, 2021 were $132.5M. This cash position does not include the $54M upfront payment Voyager is entitled to receive from Novartis as part of the Novartis license option agreement announced on March 8. "We're extremely pleased with the value created by our TRACER capsid discovery platform, evidenced by the two major license option agreements with Novartis and Pfizer for target-specific access to our highly differentiated capsids, which affords us the opportunity to expand the impact of our technology through external program development by our partners. The potential of our novel TRACER capsids to improve transduction in target tissues and to minimize off target toxicities associated with conventional AAV delivery may enable a new wave of gene therapies to treat serious diseases," said Michael Higgins, interim CEO of Voyager. "We've also made important additions to our leadership team with Al Sandrock joining our Board and its Executive Committee, and the promotion of Robin Swartz to chief operating officer. We continue to leverage our proprietary AAV capsids to progress our pipeline and look forward to sharing new preclinical data from select programs and our TRACER platform at a medical conference this spring."
 
TrailerParkTed said:
The stocks QUAD and VYGR any thoughts? Holding since a $5.80 ave and $6 respectively.
More...


These are new to me Ted but Voyager is really interesting. I would forget the other one.

stk has gone from $4--$8 on this huge deal with Novartis but look--

Voyager Therapeutics
Most biotech stocks have performed dismally this year. Not Voyager Therapeutics ( VYGR 3.30% ). Its shares are up an impressive 250% year to date.

Voyager delivered this huge gain by striking a deal with a huge drugmaker. Earlier this month, the company announced a licensing agreement with Novartis that could eventually be worth more than $1.5 billion. Granted, only $91.5 million of that total will come in the first 12 months of the collaboration. However, the news nonetheless excited investors.



NASDAQ: VYGR
Voyager Therapeutics
Today's Change
(3.30%) $0.25
Current Price
$7.82


Key Data Points
Market Cap
$289M
Day's Range
$7.45 - $8.34
52wk Range
$2.46 - $9.74
Volume
581,955
Avg Vol
768,422
P/E (ttm)

Novartis isn't the only big pharma company interested in Voyager's adeno-associated virus (AAV) capsid platform. Pfizer partnered with Voyager last October. Both Novartis and Pfizer think that Voyager's platform holds the potential to deliver gene therapies with fewer toxicity issues than conventional AAVs.


 
You must log in or register to reply here.
Back
Top